Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management
May 19 2009 - 11:00AM
PR Newswire (US)
Collaboration combines insulin expertise of Lilly with Medtronic
delivery and glucose sensing leadership INDIANAPOLIS and
MINNEAPOLIS, May 19 /PRNewswire-FirstCall/ -- Two of the most
recognized names in diabetes management -Eli Lilly and Company
(NYSE: LLY) and Medtronic, Inc. (NYSE:MDT) - today announced a
strategic marketing collaboration to bolster each company's
commitment to help people with diabetes manage their blood sugar
using insulin therapy. Working collaboratively with health care
professionals, Lilly and Medtronic marketing and sales operations
in the United States will work to improve the delivery of diabetes
education for people and caregivers affected by type 1 diabetes -
including the development of new educational resources and classes
around the initiation and intensive management of insulin, insulin
pump therapy and continuous glucose monitoring (CGM). The alliance
combines the insulin expertise of Lilly - a worldwide leader in
diabetes treatment, research and education - with the advanced
diabetes technologies of Medtronic, the world's largest
manufacturer of insulin pumps and CGM and maker of the world's only
integrated diabetes management system that combines the power of
insulin pump therapy with CGM. "Medtronic and Lilly are joining
together to help improve patient access to high quality diabetes
education," said Chris O'Connell, president of the diabetes
business unit and senior vice president at Medtronic. "Because
diabetes management is complicated, it is crucial that physicians
and patients have the best access to information and educational
resources. This collaboration will generate greater awareness and
enable more people to benefit from the latest educational tools
regarding insulin pump therapy and continuous glucose monitoring."
"People with diabetes have numerous treatment options and devices
to help manage blood sugar, but physicians and patients need
resources and solutions to integrate these improvements into
real-world therapy," said Matt Beebe, diabetes brand leader, Lilly
USA, LLC. "With this alliance, Lilly and Medtronic hope to create
integrated solutions to address challenges for people taking
insulin who need optimal glycemic control. By joining forces, we
will help make insulin therapy more achievable by offering new
educational materials and resources that help make insulin pump
therapy fit into patients' lives." Both companies are dedicated to
improving the overall patient experience and bring trusted
reputations along with a history of firsts in diabetes care.
Medtronic has been well-established as the leader in insulin
delivery innovation since it introduced the world's first insulin
pump in 1983, and has been improving on the technology for more
than 25 years. Medtronic continued to innovate with the first CGM
system approved for physician use in 1999, the first patient-use
CGM in 2003 and the most advanced Web-based therapy management
system in 2004. Lilly has long been the leading innovator in
insulin therapy; Lilly introduced the world's first insulin for
public use in 1923 and has continued to introduce advances in
diabetes therapy over the next 85 years. About Diabetes According
to the Centers for Disease Control and Prevention, diabetes affects
nearly 24 million Americans; of that, nearly one-quarter, or nearly
six million people, do not know they have the disease.(1) Diabetes
is the sixth leading cause of death in the United States and costs
approximately $174 billion per year in direct and indirect medical
expenses.(1,2) About the Diabetes Business at Medtronic The
Diabetes business at Medtronic (http://www.medtronicdiabetes.com/)
is the world leader in advanced diabetes management solutions,
including integrated diabetes management systems, insulin pump
therapy, continuous glucose monitoring systems and therapy
management software. About Medtronic Medtronic, Inc.
(http://www.medtronic.com/), headquartered in Minneapolis, is the
global leader in medical technology, alleviating pain, restoring
health and extending life for millions of people around the world.
About Lilly Diabetes For more than 85 years, Lilly has been a
worldwide leader in pioneering industry-leading solutions to
support people living with and treating diabetes. Lilly introduced
the world's first commercial insulin in 1923, and remains at the
forefront of medical and delivery device innovation to manage
diabetes. Lilly is also committed to providing solutions beyond
therapy -- practical tools, education and support programs to help
overcome barriers to success along the diabetes journey. At Lilly,
the journey of each person living with or treating diabetes
inspires ours. For more information, visit
http://www.lillydiabetes.com/ About Eli Lilly and Company Lilly, a
leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical
products by applying the latest research from its own worldwide
laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides
answers -- through medicines and information -- for some of the
world's most urgent medical needs. Information about Lilly is
available at http://www.lilly.com/. (1) Centers for Disease Control
and Prevention (CDC). National diabetes fact sheet: general
information and national estimates on diabetes in the United
States, 2007. Rev ed. Atlanta, GA: U.S. Department of Health and
Human Services, Centers for Disease Control and Prevention, 2008
(2) American Diabetes Association. Direct and indirect costs of
diabetes in the United States. Available at:
http://www.diabetes.org/diabetes-statistics/cost-of-diabetes-in-us.jsp.
Accessed January 16, 2009 P-LLY (Logo:
http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO ) (Logo:
http://www.newscom.com/cgi-bin/prnh/20080519/DE19417LOGO )
http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO
http://www.newscom.com/cgi-bin/prnh/20080519/DE19417LOGO
http://photoarchive.ap.org/ DATASOURCE: Eli Lilly and Company
CONTACT: J. Scott MacGregor, Public Relations of Eli Lilly and
Company, +1-317-651-1494, mobile, +1-317-440-4699; or Steve
Sabicer, Public Relations, +1-818-576-4826, mobile,
+1-714-907-6264, or Investors, Jeff Warren, +1-763-505-2696, both
of Medtronic, Inc.
Copyright